Biotie Therapies - Company Announcement

Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

BIOTIE THERAPIES CORP.      STOCK EXCHANGE RELEASE       7 April 2011, at 9.00
a.m.



Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

Turku, Finland, April 7th 2011- Biotie Therapies Corp., a development stage
company focused on diseases of the central nervous system, today announced  the
start of a Phase 2b trial evaluating SYN115 in Parkinson's Disease (PD). Results
from the study are expected in the first half of 2013.

SYN115 is an orally bioavailable potent and selective adenosine A2a receptor
antagonist. Adenosine A2a inhibition has been shown in preclinical studies to
reverse motor deficits and enhance the effect of current PD therapies, e.g.
levodopa and dopamine agonists, without inducing troublesome dyskinesia
(involuntary movements). In addition, SYN115 also displays activity in
preclinical models on non-motor symptoms of PD including depression, cognition
and anxiety.

The Phase 2b trial is a randomized, double-blind, placebo-controlled study that
will evaluate four doses of SYN115 versus placebo as adjunctive therapy in 400
levodopa-treated PD patients with end of dose wearing off.  In these patients,
treatment with levodopa is insufficient to control PD symptoms until their next
dose, resulting in an 'off' period when symptoms reappear. The aim of the Phase
2b study is to determine the efficacy and safety of SYN115 in reducing the mean
time spent in the 'off' state over a 12 week treatment period. The trial will
also assess the impact of SYN115 on various measures of motor symptom severity,
dyskinesia and non-motor symptoms.

 "SYN115 is the lead product coming from our recent acquisition of Synosia and
we are very pleased to advance this promising candidate into late-stage clinical
development," said Timo Veromaa, President and Chief Executive Officer of
Biotie. "Despite the availability of treatments for Parkinson's Disease, there
remains a significant unmet medical need for therapies with an alternative
mechanism of action and SYN115 could be the first drug with a novel mechanism of
action in PD for a generation."

Biotie has granted UCB Pharma S.A. a license for exclusive, worldwide rights to
SYN115. UCB will be responsible for Phase 3 development and commercialization.

In Turku, 7 April 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Dr. Stephen Bandak, Chief Medical Officer
tel. +1 650 296 0946 (Pacific Daylight Time)
email:stephen.bandak@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com
www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media



About SYN115

SYN115 is an orally bioavailable, potent and selective adenosine A2a receptor
antagonist, which enters the brain and modulates regions associated with motor
and non-motor function. Biotie obtained development and commercialization rights
to SYN115 from Roche in 2007 for selected diseases of the central nervous system
and has an option to rights for development in all indications.

About Parkinson's disease

Parkinson's disease is the second most common neurodegenerative disorder, after
Alzheimer's disease. It affects about one percent of people ages 65-69, rising
to up to three percent of people who are 80 years and older. The symptoms of
Parkinson's disease result from decreased dopamine production in regions of the
brain controlling movement.

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (Parkinson's disease,
Alzheimer's disease and other cognitive disorders, bipolar disorder, and alcohol
and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis,
chronic obstructive pulmonary disease and others). It has several innovative
small molecule and biological drug candidates at different stages of clinical
development. Biotie's products address diseases with high unmet medical need and
significant market potential.

Partnerships with top/tier pharmaceutical partners are in place for several
programs  as well as a strategic collaboration with UCB Pharma S.A. Biotie's
most advanced product, nalmefene for alcohol dependence, is currently in Phase
3 clinical development by licensing partner H. Lundbeck A/S.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.




[HUG#1504261]